Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSKVX000000030810
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSKVX000000030810 is a sponsor-specific identifier for a component of **GSK3943104**, an investigational **HSV-targeted immunotherapy** developed by **GSK** (GlaxoSmithKline). This therapeutic vaccine is designed for the treatment of **genital herpes** caused by **herpes simplex virus type 2 (HSV-2)**. The immunotherapy aims to reduce the frequency of clinical recurrences and viral shedding in individuals already infected with the virus. It typically comprises recombinant HSV-2 antigens (such as glycoprotein D, glycoprotein B, and the immediate-early protein ICP4) formulated with the **AS01 adjuvant system**, which is intended to boost the cellular immune response, particularly CD4+ T-cells. GSK3943104 is currently being evaluated in Phase I/II clinical trials, including the THESEUS study, to determine its safety, immunogenicity, and preliminary efficacy in both healthy adults and those with recurrent genital herpes.
- Other names
- HSV-targeted immunotherapy
02
Targets
gD (HSV-2 glycoprotein D)
Beyond the preview
Go deeper on GSKVX000000030810.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSKVX000000030810.